Jonas B. Galper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonas B. Galper has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Serban P. Georgescu
3 shared publicationsC. Michael Welzig
2 shared publicationsHo-Jin Park
Tufts New England Medical Center
2 shared publications- Ho-Jin Park
Molecular Cardiology Research Institute, Department of Medicine, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA
2 shared publications Yali Zhang
2 shared publicationsAlexander G. Papageorge
NCI National Institutes of Health 20892 Bethesda Maryland
1 shared publication
Latest Publications
- Open Access
- 2 January 2008
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 118 (1) , 259-271
Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP
Parasympathetic stimulation of the heart, which provides protection from arrhythmias and sudden death, involves activation of the G protein–coupled inward rectifying K+ channel GIRK1/4 and results in an acetylcholine-sensitive K+ current, IKACh. We describe a unique relationship between lipid homeostasis, the lipid-sensitive transcription factor SREBP-1, regulation of the cardiac parasympathetic response, and the development of ventricular arrhythmia. In embryonic chick atrial myocytes, lipid lowering by culture in lipoprotein-depleted serum increased SREBP-1 levels, GIRK1 expression, and IKACh activation. Regulation of the GIRK1 promoter by SREBP-1 and lipid lowering was dependent on interaction with 2 tandem sterol response elements and an upstream E-box motif. Expression of dominant negative SREBP-1 (DN–SREBP-1) reversed the effect of lipid lowering on IKACh and GIRK1. In SREBP-1 knockout mice, both the response of the heart to parasympathetic stimulation and the expression of GIRK1 were reduced compared with WT. IKACh, attenuated in atrial myocytes from SREBP-1 knockout mice, was stimulated by SREBP-1 expression. Following myocardial infarction, SREBP-1 knockout mice were twice as likely as WT mice to develop ventricular tachycardia in response to programmed ventricular stimulation. These results demonstrate a relationship between lipid metabolism and parasympathetic response that may play a role in arrhythmogenesis.
- 2 January 2008
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 118 (1) , 259-271
Open AccessParasympathetic response in chick myocytes and mouse heart is controlled by SREBP
Parasympathetic stimulation of the heart, which provides protection from arrhythmias and sudden death, involves activation of the G protein–coupled inward rectifying K+ channel GIRK1/4 and results in an acetylcholine-sensitive K+ current, IKACh. We describe a unique relationship between lipid homeostasis, the lipid-sensitive transcription factor SREBP-1, regulation of the cardiac parasympathetic response, and the development of ventricular arrhythmia. In embryonic chick atrial myocytes, lipid lowering by culture in lipoprotein-depleted serum increased SREBP-1 levels, GIRK1 expression, and IKACh activation. Regulation of the GIRK1 promoter by SREBP-1 and lipid lowering was dependent on interaction with 2 tandem sterol response elements and an upstream E-box motif. Expression of dominant negative SREBP-1 (DN–SREBP-1) reversed the effect of lipid lowering on IKACh and GIRK1. In SREBP-1 knockout mice, both the response of the heart to parasympathetic stimulation and the expression of GIRK1 were reduced compared with WT. IKACh, attenuated in atrial myocytes from SREBP-1 knockout mice, was stimulated by SREBP-1 expression. Following myocardial infarction, SREBP-1 knockout mice were twice as likely as WT mice to develop ventricular tachycardia in response to programmed ventricular stimulation. These results demonstrate a relationship between lipid metabolism and parasympathetic response that may play a role in arrhythmogenesis.
- Open Access
- 1 July 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (29) , 19995-20002
Transforming Growth Factor β Regulates the Expression of the M2 Muscarinic Receptor in Atrial Myocytes via an Effect on RhoA and p190RhoGAP
- 1 July 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (29) , 19995-20002
Open AccessTransforming Growth Factor β Regulates the Expression of the M2 Muscarinic Receptor in Atrial Myocytes via an Effect on RhoA and p190RhoGAP
- 2 December 2003
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (22) , 2743-2746
Lipid Lowering by Pravastatin Increases Parasympathetic Modulation of Heart Rate
Background— We have previously demonstrated in an in vitro model for lipid lowering that lipoprotein depletion resulted in a marked increase in the negative chronotropic response to the acetylcholine analogue carbamylcholine. In this study we used heart rate variability analysis to determine the effect of lipid lowering by statins on the response of the heart to parasympathetic stimulation. In parallel, we examined whether changes in parasympathetic responsiveness correlated with changes in the expression of Gα i2 , a molecular component of the parasympathetic signaling pathway in the heart. Methods and Results— Patients were randomized in a crossover study of pravastatin and simvastatin. R-R interval analysis of Holter monitor studies demonstrated that in patients treated initially with pravastatin, the peak high-frequency power fraction during sleep, which reflects parasympathetic modulation of heart rate, increased by 24.0±5.02% (SEM, n=13, P P =0.009) increase in Gα i2 expression, whereas simvastatin had no effect. Relative changes in Gα i2 correlated significantly with the changes in the fraction of high-frequency power (ρ=0.574, P =0.016). Conclusions— Taken together with our in vitro data, these data are the first to suggest that cholesterol lowering by pravastatin might increase the response of the heart to parasympathetic stimulation and that changes in Gα i2 expression might serve as a molecular marker for this effect.
- 2 December 2003
- Published by Wolters Kluwer Health in Circulation
- Vol. 108 (22) , 2743-2746
Lipid Lowering by Pravastatin Increases Parasympathetic Modulation of Heart Rate
Background— We have previously demonstrated in an in vitro model for lipid lowering that lipoprotein depletion resulted in a marked increase in the negative chronotropic response to the acetylcholine analogue carbamylcholine. In this study we used heart rate variability analysis to determine the effect of lipid lowering by statins on the response of the heart to parasympathetic stimulation. In parallel, we examined whether changes in parasympathetic responsiveness correlated with changes in the expression of Gα i2 , a molecular component of the parasympathetic signaling pathway in the heart. Methods and Results— Patients were randomized in a crossover study of pravastatin and simvastatin. R-R interval analysis of Holter monitor studies demonstrated that in patients treated initially with pravastatin, the peak high-frequency power fraction during sleep, which reflects parasympathetic modulation of heart rate, increased by 24.0±5.02% (SEM, n=13, P P =0.009) increase in Gα i2 expression, whereas simvastatin had no effect. Relative changes in Gα i2 correlated significantly with the changes in the fraction of high-frequency power (ρ=0.574, P =0.016). Conclusions— Taken together with our in vitro data, these data are the first to suggest that cholesterol lowering by pravastatin might increase the response of the heart to parasympathetic stimulation and that changes in Gα i2 expression might serve as a molecular marker for this effect.